| pubmed-article:2411676 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2411676 | lifeskim:mentions | umls-concept:C0699885 | lld:lifeskim |
| pubmed-article:2411676 | lifeskim:mentions | umls-concept:C0751571 | lld:lifeskim |
| pubmed-article:2411676 | lifeskim:mentions | umls-concept:C1369034 | lld:lifeskim |
| pubmed-article:2411676 | lifeskim:mentions | umls-concept:C0016263 | lld:lifeskim |
| pubmed-article:2411676 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:2411676 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2411676 | pubmed:dateCreated | 1985-10-17 | lld:pubmed |
| pubmed-article:2411676 | pubmed:abstractText | Thirty-eight transitional-cell carcinomas (TCC) were analyzed by flow cytometry (FCM) using propidium iodide for DNA analysis and antibodies to cytokeratin by indirect immunofluorescence. By means of two-dimensional FCM analysis, cytokeratin-positive tumor cells could be analysed separately from cytokeratin-negative stromal and inflammatory cells. This resulted in an 18% increase in sensitivity of FCM detection of aneuploidy (10/38 samples with one-parameter DNA analysis versus 15/38 samples with two-parameter DNA and cytokeratin analysis). In addition, S-phase could be determined in the 15 aneuploid samples by means of two-parameter analysis where this was not possible using only DNA content because of the overlap of diploid and aneuploid populations. FCM analysis allowed quantification of the percentage of tumor cells expressing cytokeratin 18 which has previously been shown to correlate quantitatively with higher grade, higher stage TCC. The quantitative measurement of tumor-cell expression of cytokeratin 18 by FCM analysis appears to provide additional information of potential prognostic value, independent of tumor-cell ploidy and proliferative fractions. | lld:pubmed |
| pubmed-article:2411676 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2411676 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2411676 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2411676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2411676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2411676 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2411676 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2411676 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2411676 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:HermanC JCJ | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:DebruyneF MFM | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:RamaekersF... | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:VooijsG PGP | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:BeckH LHL | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:SmeetsA WAW | lld:pubmed |
| pubmed-article:2411676 | pubmed:author | pubmed-author:FeitzW FWF | lld:pubmed |
| pubmed-article:2411676 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2411676 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2411676 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:2411676 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2411676 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2411676 | pubmed:pagination | 349-56 | lld:pubmed |
| pubmed-article:2411676 | pubmed:dateRevised | 2007-7-24 | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:meshHeading | pubmed-meshheading:2411676-... | lld:pubmed |
| pubmed-article:2411676 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:2411676 | pubmed:articleTitle | Tissue-specific markers in flow cytometry of urological cancers: cytokeratins in bladder carcinoma. | lld:pubmed |
| pubmed-article:2411676 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2411676 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2411676 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2411676 | lld:pubmed |
